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Currently, a selection of good, albeit not perfect, prosthetic heart valves (PHVs) with data on
patient outcomes with follow-up times of 15 to 20 years or longer is available. The “next
generation” of PHVs have some interesting features, but there are no data on patient
outcomes at 15 to 20 years. The history of PHVs is that: 1) major advances have come in
small increments, and 2) extrapolations made from early results were not correct at long term,
and when this occurred, patients paid the price in terms of mortality and morbidity. Thus,
great enthusiasm from early results and premature prediction may be inappropriate. The data
on long-term outcomes are needed and in 2003 one should preferentially select a PHV with
proven long-term results. (J Am Coll Cardiol 2003;42:1720–1) © 2003 by the American
College of Cardiology Foundation
“Prediction is very difficult, especially about the future.”
—Niels Bohr, Danish physicist, 1885 to 1962
In this issue of the Journal, Bach has presented an interest-
ing article (1) (hereafter referred to as Viewpoint) regarding
the choice of the next generation of prosthetic heart valves
(PHVs). His hypotheses are that: 1) the recommendations
in a recent “review” (2) are inappropriate for the current
time because they are based “heavily on the randomized
trials” initiated in the late 1970s; and 2) outcomes with use
of “newer” PHVs have been shown to be superior, for
example, with use of stentless porcine versus stented porcine
PHV. Presumably, these hypotheses are meant to be pro-
vocative; nevertheless, they need to be examined critically.
See page 1717
The review (2) devoted only about 5% of space to the
trials. Actually, the review (2) stated the choice of a PHV
should be based on several factors, including known long-
term results from randomized trials and databases, patient
characteristics, expected survival of the patient, and unique
patient needs, and also emphasized in the text, Figure 8, and
the abstract that in individual patients there may be excep-
tions to the general rules.
The Viewpoint (1) also stated that in the Department of
Veterans Administration (DVA) trial, all the valve-related
morbidity with bioprostheses “comprised predominantly of
late structural failure.” Actually, at 15 years, after aortic valve
replacement (AVR), the incidence of “primary valve failure”
comprised only 35% of all complications (3). In addition,
the Viewpoint (1) stated that the end point of all valve-
related “morbidity” with bioprostheses was superior to
mechanical valves “prior to 12 years after surgery” (1).
Figure 1 from the Viewpoint (1), which is from the DVA
trial, actually shows that for AVR, the total complication
rates were virtually identical in the first 2 years and from
years 9 to 16. The major cause of the difference in morbidity
in the years 3 through 8 was increased bleeding with
mechanical PHV, and it was strongly emphasized and
discussed in the DVA trial reports that the increased
bleeding was at least partly due to the level of anticoagula-
tion, which was excessively high (2,3). Only AVR is
emphasized because the Viewpoint mainly discusses this
PHV with regard to newer bioprostheses.
With regard to superiority of newer PHVs, space limita-
tions allow a critical evaluation only of the statement that
some newer bioprostheses have “statistically significant sur-
vival advantages.” The Viewpoint (1) cites three studies
(4–6) that have compared mortality at two to eight years
after implantation of a stentless versus a stented aortic
porcine PHV. The data from the study with the longest
follow-up (4) are shown in Table 1. In all three studies
(4–6), in both subgroups the late mortality was largely due
to deaths from other cardiac and non-cardiac causes, which
were greater in the group that received the stented valve.
Therefore, it is important to know the associated comorbid
conditions at baseline and their treatment that could ac-
count for the late deaths (7). However, all three studies
(4–6) provided no information about smoking, body mass
index, previous myocardial infarction, clinical heart failure,
lipids, hypertension, and chronic obstructive pulmonary
disease, and two studies (4,6) also did not provide informa-
tion about diabetes, renal failure, atrial fibrillation, New
York Heart Association functional class III and/or IV, and
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coronary artery disease. A more recent study (8) also was
cited in the Viewpoint (1). In this study, the patients were
selected from the database of the devices manufacturer (8);
moreover, it also has problems similar to the other three
cited studies (4–6). Thus, it is questionable whether the
current data support the superiority of survival with use of a
stentless valve. Indeed, Westaby et al. (5) have stated that
“Ideally, the question: ‘do stentless valves convey survival
benefit?’ should be addressed by a prospective randomized
trial.”
In conclusion: 1) the “next generation” of PHVs must
undergo rigorous testing to determine the patient outcomes
on long-term follow-up (15 to 20 years); 2) these PHVs
must be documented to confer the same or better outcomes
as the “older” good PHVs currently available; and 3) the
long-term results are only partly related to the PHV, for
example, only 40% to 50% of total mortality is related to the
PHV (2,3). Therefore, one should not compare, or at least
be extremely cautious about comparing, outcomes with use
of different PHVs, or even the same brand of PHV from
different studies, unless all the major and important baseline
characteristics (cardiac and non-cardiac) and their treatment
are identical or at least very similar (2).
Choice of PHV: 2003. Careful and scholarly review of the
literature is important and is advised. Long-term data are
not available for the newer prostheses; therefore, it was
suggested that clinicians “draw conclusions and make rec-
ommendations based on incomplete information, extrapo-
lating from limited data, clinical experience, and common
sense” (1). Voltaire once stated that “Common sense is not
so common.” Prosthetic heart valves were introduced into
clinical medicine 43 years ago, and in the early era (1960s
and 1970s) patients undergoing PHV were usually sicker
and long-term follow-up data were not available. Therefore,
extrapolations from early data to possible longer-term re-
sults, although speculative, were appropriate at that time.
The history of PHVs is that a very large number of PHVs
initially had seemed good and logical extrapolations that
were made were later found to be incorrect. As a result, only
a few PHVs have lasted, and in those patients in whom the
PHVs did not last, the patients paid the price in terms of
morbidity and mortality; it needs to be re-emphasized the
patient and not the physicians is taking the risks associated
with use of PHVs (2). The clinical situation is very different
now; a selection of good, albeit not perfect, PHVs with data
on patient outcomes with follow-up times of 15 to 20 years
or longer is available. This information must be considered
in selecting a PHV.
The search for an ideal (perfect) PHV must continue.
However, history shows that major advances in PHVs have
come in small increments (2) and, thus, one should be very
cautious about inappropriate enthusiasm and premature
prediction of an expected much better long-term result with
“newer” PHVs.
At present, it seems appropriate that: 1) a PHV not yet
approved for clinical use by the Food and Drug Adminis-
tration should be inserted as part of an approved research
protocol; 2) if a patient’s expected life expectancy is 10
years and one is recommending a PHV with favorable
follow-up data of only 10 years, then one should take care
to accurately and precisely so inform the patient who should
also be informed about potential risks and benefits with use
of such a PHV; it is prudent and important that the
information provided to the patient is adequately docu-
mented; and 3) if a patient’s expected life expectancy is 10
years, then one should preferably choose a PHV with
known favorable patient outcomes data of 15 to 20 years.
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Table 1. Causes of Late Deaths
Toronto SPV
(Stentless PHV)
Hancock II
(Stented PHV)
Cardiac and valve related
Myocardial infarction/sudden 3 5
Congestive heart failure 1 6
Prosthetic valve endocarditis 1 2
Stroke 0 2
Total 5 15
Noncardiac deaths
Cancer 2 5
Renal failure 0 2
Abdominal aortic aneurysm 0 2
Pneumonia 0 1
Cerebral aneurysm 1 0
Suicide 1 0
Total 4 10
Adapted from David et al. (4).
PHV  prosthetic heart valve; SPV  stentless porcine valve.
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